Get the Stockscreener App
210.39
2.93%
-6.36
Jazz Pharmaceuticals Plc stock is traded at $210.39, with a volume of 817.95K.
It is down -2.93% in the last 24 hours and down -14.41% over the past month.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
See More
Previous Close:
$216.75
Open:
$216.86
24h Volume:
817.95K
Relative Volume:
0.93
Market Cap:
$13.66B
Revenue:
$4.44B
Net Income/Loss:
$29.49M
P/E Ratio:
-11,434.24
EPS:
-0.0184
Net Cash Flow:
$1.19B
1W Performance:
-9.08%
1M Performance:
-14.41%
6M Performance:
+7.72%
1Y Performance:
+55.68%
1-Day Range:
$209.34
$216.86
1-Week Range:
$209.34
$235.54
52-Week Range:
$128.80
$266.38
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Name
Jazz Pharmaceuticals Plc
Sector
Industry
Phone
353-1-634-7800
Address
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Compare JAZZ vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
210.39 | 13.66B | 4.44B | 29.49M | 1.19B | -0.0184 |
VRTX
Vertex Pharmaceuticals Inc
|
485.22 | 122.98B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
216.25 | 86.33B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
753.12 | 77.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
802.64 | 50.47B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.44 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-26 | Initiated | Citigroup | Buy |
| Sep-24-26 | Resumed | Goldman | Buy |
| Jul-17-26 | Initiated | Canaccord Genuity | Buy |
| Jun-09-26 | Resumed | Truist | Buy |
| May-22-26 | Initiated | Bernstein | Mkt Perform |
| May-19-26 | Upgrade | UBS | Neutral → Buy |
| Apr-10-26 | Resumed | Raymond James | Outperform |
| Feb-27-26 | Initiated | Barclays | Overweight |
| Nov-24-25 | Downgrade | UBS | Buy → Neutral |
| Jul-15-25 | Initiated | Deutsche Bank | Buy |
| Mar-07-25 | Upgrade | UBS | Neutral → Buy |
| Feb-26-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-13-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-12-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-05-24 | Initiated | Goldman | Buy |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Nov-27-23 | Downgrade | UBS | Buy → Neutral |
| Sep-29-23 | Initiated | Raymond James | Mkt Perform |
| Jun-12-23 | Resumed | Wells Fargo | Equal Weight |
| Dec-09-22 | Upgrade | Goldman | Neutral → Buy |
| Jun-14-22 | Initiated | UBS | Buy |
| Apr-06-22 | Downgrade | Goldman | Buy → Neutral |
| Nov-19-21 | Resumed | Goldman | Buy |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Oct-05-21 | Initiated | Citigroup | Buy |
| Sep-23-21 | Initiated | Needham | Buy |
| May-19-21 | Resumed | JP Morgan | Overweight |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-05-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-03-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-29-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-16-20 | Initiated | UBS | Buy |
| Nov-03-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-09-20 | Reiterated | H.C. Wainwright | Buy |
| Sep-14-20 | Downgrade | Goldman | Neutral → Sell |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Aug-06-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-28-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jul-23-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-06-20 | Initiated | Jefferies | Buy |
| Mar-12-20 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-08-20 | Initiated | Goldman | Neutral |
| Aug-21-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jun-11-19 | Initiated | Barclays | Overweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Dec-14-18 | Initiated | Wolfe Research | Peer Perform |
| Nov-08-18 | Reiterated | B. Riley FBR | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Jul-11-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-23-18 | Reiterated | H.C. Wainwright | Neutral |
| Mar-19-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Jazz Pharmaceuticals Plc Stock (JAZZ) Latest News
Jim Cramer Gives Green Light To This Health Care Stock - Benzinga
Jazz Pharmaceuticals (JAZZ) President & CEO Renee Gala Sells 2,0 - GuruFocus
Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock - Zacks Investment Research
Jazz Pharmaceuticals plc (J7Z.F) Stock Price, News, Quote & History - Yahoo! Finance Canada
The top 12 companies hiring in biopharma now - BioSpace
Q2 Earnings Outperformers: Jazz Pharmaceuticals (NASDAQ:JAZZ) And The Rest Of The Pharmaceuticals Stocks - Yahoo Finance
What Comes Next for Jazz Pharmaceuticals (NASDAQ:JAZZ)? - Kalkine Media
Jazz Pharmaceuticals plc (JAZZ) stock price, news, quote and history - Yahoo Finance Singapore
Jazz Pharmaceuticals Targets $5B Zanidatamab Opportunity as Oncology Revenue Tops $1B - Yahoo Finance
Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expands - Yahoo Finance
What Makes the Latest Jazz Pharmaceuticals (JAZZ) Story Different? - Kalkine Media
Ajit Baid Joins Jazz Pharmaceuticals as Executive Director, Head of Marketing – EMD Franchise - hrtoday.in
Should You Buy Jazz Pharmaceuticals Stock After Its Actio Acquisition? - Yahoo Finance
Jazz Pharmaceuticals (JAZZ) Places An $820M Epilepsy Bet - Yahoo Finance
Jazz Pharmaceuticals Completes $820 Million Acquisition of Actio Biosciences - BioBuzz
Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences - PR Newswire
Jazz Pharmaceuticals (JAZZ) Wins On Ziihera Data, Is It Still 15% Below Fair Value? - simplywall.st
Jazz Pharmaceuticals (JAZZ) Wins On Ziihera Data, Is It Still 15% Below Fair Value? - simplywall.st
ETFs Investing in Jazz Pharmaceuticals Public Limited Company Stocks - TradingView
Jazz Pharmaceuticals Sees Meaningful Long-Term Value From Ziihera's Pursuits Beyond GEA, UBS Says - marketscreener.com
JAZZ Maintained by UBS -- Price Target Raised to $337 - GuruFocus
UBS raises Jazz Pharmaceuticals stock price target on Ziihera approval - Investing.com
UBS raises Jazz Pharmaceuticals stock price target on Ziihera approval By Investing.com - Investing.com India
UBS raises Jazz Pharmaceuticals stock price target on Ziihera approval By Investing.com - Investing.com UK
UBS Adjusts Jazz Pharmaceuticals PT to $337 From $315, Maintains Buy Rating - marketscreener.com
ETFs Investing in Jazz Pharmaceuticals Public Limited Company Stocks - tradingview.com
2 Reasons to Avoid JAZZ and 1 Stock to Buy Instead - Yahoo Finance
UBS raises Jazz Pharmaceuticals stock price target on Ziihera approval By Investing.com - Investing.com South Africa
Jazz Pharmaceuticals SVP Mary Elizabeth Henderson Sells Shares to Cover RSU Tax Withholding - Kalkine Media
Jazz Pharmaceuticals (NASDAQ: JAZZ) exec to sell restricted stock - Stock Titan
Jazz Pharmaceuticals at citigroup summit: rare-disease push gains pace By Investing.com - Investing.com Nigeria
JAZZ: Record growth, new launches, and AI-driven strategies fuel rare disease expansion and raised outlook - TradingView
Jazz Pharmaceuticals at citigroup summit: rare-disease push gains pace - Investing.com
Jazz Pharmaceuticals at citigroup summit: rare-disease push gains pace By Investing.com - Investing.com UK
JAZZ Maintained by Barclays -- Price Target Raised to $271 - GuruFocus
Jazz Pharmaceuticals at Wells Fargo conference: growth broadens By Investing.com - Investing.com India
Jazz Pharmaceuticals at Wells Fargo conference: growth broadens By Investing.com - Investing.com Canada
Jazz Pharmaceuticals at Wells Fargo conference: growth broadens By Investing.com - Investing.com UK
Jazz Pharmaceuticals debt upgraded by S&P on stronger recovery By Investing.com - Investing.com Australia
Jazz Pharmaceuticals (JAZZ) Stock Looks Reasonable On Value While Returns Look Stretched - simplywall.st
Jazz Pharmaceuticals (JAZZ) Stock Looks Reasonable On Value While Returns Look Stretched - simplywall.st
JAZZ: Record revenue, pipeline expansion, and rare disease focus drive strong growth outlook - TradingView
Jazz Pharma (NASDAQ: JAZZ) exec plans $486K Rule 144 stock sale - Stock Titan
Jazz Pharmaceuticals (JAZZ) director moves to sell more stock - Stock Titan
Jazz Pharmaceuticals debt upgraded by S&P on stronger recovery - Investing.com Nigeria
Jazz Pharmaceuticals debt upgraded by S&P on stronger recovery - Investing.com India
Jazz Pharmaceuticals debt upgraded by S&P on stronger recovery - Investing.com South Africa
Jazz Pharmaceuticals debt upgraded by S&P on stronger recovery - Investing.com Canada
Jazz Pharmaceuticals debt upgraded by S&P on stronger recovery - investing.com
Jazz Pharmaceuticals debt upgraded by S&P on stronger recovery - Investing.com UK
Jazz Pharmaceuticals Plc Stock (JAZZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
Jazz Pharmaceuticals Plc Stock (JAZZ) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| GALA RENEE D | President & CEO |
Oct 06 '26 |
Sale |
236.40 |
2,000 |
472,800 |
141,394 |
| RENEE D GALA | Officer |
Oct 06 '26 |
Proposed Sale |
236.40 |
2,000 |
472,800 |
0 |
| COZADD BRUCE C | Director |
Oct 01 '26 |
Sale |
230.33 |
6,000 |
1,381,980 |
345,875 |
| Bruce C Cozadd | Officer |
Oct 01 '26 |
Proposed Sale |
230.33 |
6,000 |
1,381,980 |
0 |
| Patil Neena M | EVP & Chief Legal Officer |
Sep 10 '26 |
Sale |
240.94 |
1,200 |
289,128 |
47,671 |
| NEENA PATIL | Officer |
Sep 10 '26 |
Proposed Sale |
240.94 |
1,200 |
289,128 |
0 |
| GALA RENEE D | President & CEO |
Sep 08 '26 |
Sale |
243.03 |
2,000 |
486,060 |
143,394 |
| RENEE D GALA | Officer |
Sep 08 '26 |
Proposed Sale |
243.03 |
2,000 |
486,060 |
0 |
| Henderson Mary Elizabeth | Director |
Sep 08 '26 |
Proposed Sale |
246.81 |
2,691 |
664,166 |
0 |
| COZADD BRUCE C | Director |
Sep 01 '26 |
Sale |
250.13 |
6,000 |
1,500,780 |
351,875 |
2.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):